Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc. (often referred to as NW Bio) is a pioneering biotechnology company headquartered in the United States, with significant operational activities in the field of cancer immunotherapy. Founded in 2001, the company has made notable strides in developing innovative therapies, particularly its lead product, DCVax®-L, which is designed to treat various types of cancer by harnessing the body’s immune system. With a focus on personalised medicine, Northwest Biotherapeutics stands out in the biopharmaceutical industry for its unique approach to dendritic cell therapy. The company has achieved key milestones, including successful clinical trials that underscore its commitment to advancing cancer treatment. As a leader in the immunotherapy sector, NW Bio continues to position itself at the forefront of cancer research, aiming to improve patient outcomes and redefine therapeutic standards.
DitchCarbon Score
How does Northwest Biotherapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Northwest Biotherapeutics, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Northwest Biotherapeutics, Inc.'s reported carbon emissions
Northwest Biotherapeutics, Inc., headquartered in the US, currently does not have available data on carbon emissions, as no specific emissions figures have been reported. Additionally, there are no documented reduction targets or climate pledges outlined by the company. In the absence of concrete emissions data, it is important to note that many companies in the biotherapeutics sector are increasingly focusing on sustainability and climate commitments. This trend often includes setting science-based targets for emissions reductions and implementing initiatives to minimise their carbon footprint. As the industry evolves, Northwest Biotherapeutics may consider establishing its own climate commitments to align with these emerging standards.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Northwest Biotherapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
